Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
IL13Rα2 + EGFR/EGFRvIII Dual-Target CAR-NK(Beijing Biotech) in High grade glioma: NCT07551336 Clinical Landscape Report 2026
16 September 2026
NCT07551336 clinical landscape for High grade glioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NVG-222 in Ovarian Cancer: ISRCTN13633989 Clinical Landscape Report 2026
16 September 2026
ISRCTN13633989 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Renal Cell Carcinoma: NCT07551349 Clinical Landscape Report 2026
16 September 2026
NCT07551349 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sodium Chloride in Sarcoma: NCT07553260 Clinical Landscape Report 2026
16 September 2026
NCT07553260 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Miricorilant in Metabolic Dysfunction Associated Steatohepatitis: NCT07553663 Clinical Landscape Report 2026
16 September 2026
NCT07553663 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Cysteine Hydrochloride in Glioblastoma Multiforme: NCT07553520 Clinical Landscape Report 2026
16 September 2026
NCT07553520 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TGFBR-2 KO CD70 CAR NK(The University of Texas MD Anderson Cancer Center) in Breast Cancer: NCT07553390 Clinical Landscape Report 2026
16 September 2026
NCT07553390 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
KN-3601 in Sjogren's Syndrome: NCT07558850 Clinical Landscape Report 2026
16 September 2026
NCT07558850 clinical landscape for Sjogren's Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HN-2301 in Myasthenia Gravis: NCT07556120 Clinical Landscape Report 2026
16 September 2026
NCT07556120 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Melanoma: NCT07562841 Clinical Landscape Report 2026
16 September 2026
NCT07562841 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
FT-536 in Glioblastoma: NCT07560865 Clinical Landscape Report 2026
16 September 2026
NCT07560865 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Budoprutug in Systemic Lupus Erythematosus: NCT07564596 Clinical Landscape Report 2026
16 September 2026
NCT07564596 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.